Procedures
tetanus, MenACYW-TT, Trumenba
TETANUS
Participants who had previously received a priming dose of MenACYW-TT (MenACYW-TT primed) were randomized 2:1:1 to receive a booster dose of MenACYW-TT either alone (Group 1), or co-administered with a single dose of a licensed MenB vaccine, MenB-T (Trumenba®, Pfizer, Philadelphia; Group 3) or 4CMenB (Bexsero, GSK Vaccines, Sovicille, Italy; Group 4). Participants who had previously received a priming dose of MCV4-CRM were assigned to receive a booster dose of MenACYW-TT vaccine alone (Group 2). Only laboratory technicians were blinded to treatment assignment.The booster dose of MenACYW-TT was administered intramuscularly (IM) into the deltoid muscle of the arm. Each MenACYW-TT dose was presented in 0.5 mL of saline solution containing 10 μg of each meningococcal capsular polysaccharide serogroups A, C, Y and W, and approximately 55 μg of tetanus toxoid protein carrier. MenB-T and 4CMenB were administered IM into the deltoid muscle of the opposite arm to that used for MenACYW-TT administration. Each MenB-T dose was presented in 0.5 mL containing factor H binding protein (fHBP) subfamily A, fHBP subfamily B, adsorbed on AIPO